Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

Joyce A. OShaughnessy, MD
Published: Thursday, Aug 13, 2015



Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses adding phosphoprotein testing to genomic testing for patients with breast cancer.

O’Shaughnessy explains she has often used phosphoprotein analyses in order to determine driving mutations in refractory tumors. For example, she mentions a patient with refractory triple-negative breast cancer who, upon genomic analysis, had several mutational abnormalities. Therefore, a clear treatment plan could not be determined. However, by using a phosphoprotein assay, fibroglast growth factor receptor was found to be the single driving mutation.

This is helpful, O’Shaughnessy says, because several mutational abnormalities may act as passengers and/or are inactive in patients, and the driving mutation may not be determined solely with a genomic analysis.
 


Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses adding phosphoprotein testing to genomic testing for patients with breast cancer.

O’Shaughnessy explains she has often used phosphoprotein analyses in order to determine driving mutations in refractory tumors. For example, she mentions a patient with refractory triple-negative breast cancer who, upon genomic analysis, had several mutational abnormalities. Therefore, a clear treatment plan could not be determined. However, by using a phosphoprotein assay, fibroglast growth factor receptor was found to be the single driving mutation.

This is helpful, O’Shaughnessy says, because several mutational abnormalities may act as passengers and/or are inactive in patients, and the driving mutation may not be determined solely with a genomic analysis.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x